U.S. Hospitality Stock News

If you are wondering whether Visteon at around US$90 offers genuine value or only appears cheap on the surface, this breakdown will help you frame that question clearly. The stock is around US$90.06 after a 0.7% fall over 7 days, a 14.2% drop over 30 days and a 7.0% decline year to date. The 1 year return is 12.7%, and the 3 and 5 year returns are 42.3% and 25.8% lower respectively. These mixed returns have put the focus back on what investors are paying for Visteon's future. Recent coverage...

Graphic Packaging Holding (GPK) is back on investor radar after appointing veteran automotive and industrial executive Jeffrey Stafeil to its Board of Directors, alongside a fresh amendment to its credit agreement. See our latest analysis for Graphic Packaging Holding. Despite the board refresh and credit agreement amendment, the 30 day share price return of 20.29% and the year to date share price return decline of 34.65%, alongside a 61.10% 1 year total shareholder return decline, point to...

Earlier this month, Blood Cancer United and Tempus AI announced a collaboration to build a comprehensive, patient-centered real-world registry for pediatric acute myeloid leukemia, using Tempus’ olivia app and Lens analytics platform to unify data, support families, and inform research. This partnership, alongside new research showing Tempus’ advanced genomic profiling can uncover treatment-relevant findings missed by standard tests, highlights how the company’s AI and data tools are...

CVS Health (NYSE:CVS) has launched Health100, an AI powered digital health engagement platform. The company is partnering with Google Cloud to support Health100 with advanced AI tools and health data interoperability. The platform is designed as an open, omni channel system that connects health data, services, and real time care engagement for consumers. CVS Health sits at the intersection of retail pharmacies, insurance, and care delivery, so any move it makes in digital health can matter...

Herc Holdings recently reported fourth-quarter 2025 revenue of US$1.21 billion, up 27.1% year on year but below analyst expectations, and issued full-year revenue and EBITDA guidance that also came in weaker than the market had anticipated. The company is emphasizing integration of its June 2025 purchase of H&E, the largest acquisition in its industry, as a key lever for long-term value creation despite the softer outlook. We’ll now examine how Herc’s weaker-than-expected full-year guidance,...

Regal Rexnord recently updated investors on its CEO succession process, stating that current CEO Louis Pinkham will remain in place until June 30, 2026, or until a successor is appointed, while the board’s search committee advances its identification of several highly qualified candidates. This extended timeline and structured search process underscore the board’s emphasis on leadership continuity, an important consideration for a company executing complex integration, automation, and...

Tencent Music Entertainment Group recently reported fourth-quarter and full-year 2025 results showing higher revenue and net income year-on-year, and announced an ordinary annual cash dividend of US$0.12 per share (US$0.24 per ADS), totaling about US$368.00 million, payable to shareholders of record as of April 2, 2026. The combination of stronger earnings and a defined cash return to shareholders through the declared dividend adds fresh context to Tencent Music’s existing investment...

MPLX (NYSE:MPLX) is increasing investment in natural gas and NGL infrastructure projects. The company is emphasizing fee-based, long term contracts that are less sensitive to oil price moves. Recent geopolitical tensions affecting oil markets have not directly affected MPLX's reported business performance. For investors watching MPLX at a share price of $58.1, the focus has shifted toward how its assets in natural gas and NGLs support the current business mix. The stock has returned 7.9%...

Watts Water Technologies recently reported strong fourth-quarter and full-year 2025 results, highlighted by record financial metrics, contributions from the Haws, Superior Boiler and Saudi Cast acquisitions, and a quarterly dividend of US$0.52 per share paid on March 13, 2026. Alongside these results, management’s expectation of 8–12% sales expansion and operating margin improvement for 2026, combined with an analyst upgrade, has sharpened attention on how acquisitions and higher-margin...

Ashland recently reported past growth in its Life Sciences revenue and adjusted EBITDA, narrowed its FY2026 adjusted EBITDA outlook to US$400 million–US$420 million, and outlined roughly US$30 million of expected FY2026 savings from a broader US$90 million manufacturing optimization program. Despite headwinds from a facility outage and asbestos litigation reserves, Ashland emphasized a strong balance sheet and plans for double-digit-plus adjusted EPS growth, underscoring how cost initiatives...

Bristol-Myers Squibb's Opdualag has been introduced as a first-line immunotherapy option for advanced melanoma in NHS Scotland. The treatment combines nivolumab and relatlimab as a dual-checkpoint immunotherapy approach. This decision expands patient access to a new immunotherapy option within a major public health system. For investors tracking NYSE:BMY, this development adds a fresh real world milestone to a story that recently centered on pipeline names like mezigdomide and Sotyktu. The...

Strategy (NasdaqGS:MSTR) acquired 22,337 BTC in a single week, its largest Bitcoin purchase since January. The company now holds more than 761,000 BTC, remaining the largest public corporate holder of Bitcoin. The transaction was funded mainly through issuances of STRC preferred shares and common equity. Strategy is targeting 1 million BTC holdings by the end of 2026 as part of its Bitcoin focused corporate strategy. Strategy, formerly known as MicroStrategy, has gradually shifted from a...

Wondering if Spire's current share price still offers value, or if most of the opportunity is already priced in? This article breaks down what the numbers can and cannot tell you about that question. Spire recently closed at US$92.11, with returns of 0.3% over the past week and month, 10.7% year to date, and 25.7% over the last year, alongside 49.7% over three years and 57.5% over five years. Recent coverage around Spire has focused on its position within the gas utilities space and how...

In early 2026, U.S. Physical Therapy introduced new executive incentive and bonus plans, including restricted stock units and annual bonuses linked to Adjusted EBITDA performance targets, while analysts commented on growth opportunities, Medicare rate trends, and acquisition activity. The shift toward performance-tied equity awards and bonuses offers a clearer view of how management incentives may influence capital allocation, growth priorities, and risk-taking across the business. We will...

Intuit (NasdaqGS:INTU) executives and the company’s founder have voluntarily terminated all existing 10b5-1 pre-scheduled stock sale plans. The company plans to accelerate use of its remaining $3.5b share repurchase authorization in the second half of fiscal 2026. Leadership is presenting these moves as a clear signal of confidence in Intuit’s current valuation and long term outlook. For investors tracking Intuit at a share price of $452.31, this is being framed as a strong show of...

ADMA Biologics recently reported strong 2025 performance driven by higher demand for its immune globulin therapy ASCENIV, alongside improved payer coverage and confidence in long-term plasma supply that together provide clearer visibility into 2026 revenue acceleration. The FDA’s approval of a yield-enhancement manufacturing process is particularly important, as it is expected to lift production efficiency while supporting higher margins and longer-term capital return efforts. Now we’ll...

NCCN updated its 2026 bladder cancer guidelines to include ANKTIVA plus BCG for BCG-unresponsive non-muscle invasive bladder cancer with papillary-only disease. This recommendation extends beyond the current FDA-approved labeling, which focuses on carcinoma in situ. The change highlights a potential off-label use that could influence clinical adoption and reimbursement decisions. For investors watching ImmunityBio (NasdaqGS:IBRX), this guideline shift lands after a period of intense focus...

Fortune Brands Innovations (FBIN) is under pressure after Q4 earnings and 2026 guidance came in below expectations, followed by analyst downgrades and a 10 day, 21% share price slide. See our latest analysis for Fortune Brands Innovations. The recent Q4 earnings miss, softer 2026 guidance and leadership shake up, including interim CEO and CFO appointments and the addition of activist-backed director Ed Garden, have coincided with a fading trend in the shares, with a 30 day share price return...

Comcast (NasdaqGS:CMCSA) has rolled out major network expansions in Cheney and Clark County in Washington and in Greater Hartford/Middletown in Connecticut. The buildouts connect thousands of additional homes and businesses to multi gigabit, symmetrical internet and advanced business solutions. The company is pairing these expansions with local partnerships and digital inclusion programs in newly served communities. For you as an investor, these buildouts highlight how Comcast is working to...

Alaska Air Group recently faced a mix of developments, including sector-wide concern over rising fuel costs, ongoing integration of Hawaiian Airlines with associated layoffs and new hiring, and preparations for CEO Ben Minicucci’s fireside chat at the J.P. Morgan Industrials Conference held on March 17, 2026. Amid these pressures, institutional investors are actively adjusting their positions while Alaska Air pursues international expansion and deeper alliance ties, highlighting the tension...

Wondering whether Insmed at around US$144.60 a share looks expensive or still has room to run? This breakdown will help you connect the recent share price with what the business might be worth. The stock has seen very different return patterns, with a 1% gain over the last week, a 2.8% decline over the last month, an 18.4% decline year to date, an 85.9% return over the past year, and a very large gain over three years that is roughly 7x. Recent coverage has focused on Insmed's position in...

Raytheon, an RTX business, recently completed a US$115 million, 26,000-square-foot expansion of its Redstone Missile Integration Facility in Alabama, lifting integration and delivery capacity by over 50% and supporting more than 2,200 employees in the state. This expansion, combined with new Pentagon framework agreements to boost munitions output, underscores RTX’s role in addressing pressing missile resupply needs amid heightened geopolitical tensions. We’ll now examine how this sharp...

Eaton (NYSE:ETN) put its AI data center ambitions in the spotlight with the launch of the Beam Rubin DSX platform in partnership with NVIDIA, along with its Boyd Thermal acquisition and recent data center segment growth. See our latest analysis for Eaton. Those AI focused moves come after a mixed stretch for the stock, with a 1 month share price return of 7.25% and a 90 day share price return of 9.43%, while the 1 year total shareholder return of 22.96% and 5 year total shareholder return of...

DRDGOLD (DRD) has attracted attention after a 123.6% share price gain over the past year, supported by 33% revenue growth, as higher realized gold prices offset a 9% production decline. See our latest analysis for DRDGOLD. The 1-year total shareholder return of 130.3% sits alongside a more muted 90-day share price return of 0.69% and a 30-day share price decline of 14.22%, suggesting momentum has cooled recently after a very strong run. If DRDGOLD’s move has you curious about other gold names...